Congenital diaphragmatic hernia (CDH) may be an ideal candidate disease for in utero gene therapy as disrupted fetal lung growth plays a significant role in disease outcome. We previously demonstrated that transient in utero over expression of CFTR (cystic fibrosis transmembrane conductance regulator) during fetal development resulted in lung epithelial proliferation and differentiation. We hypothesized that gene therapy with CFTR would improve the pulmonary hypoplasia associated with CDH. CDH was induced by the herbicide 2,4-dichlorophenyl-4-nitrophyl ether (Nitrofen) following maternal ingestion at either 10 or 13 days gestation.
INTRODUCTION
Congenital diaphragmatic hernia (CDH) occurs in 1 of every 2000-4000 births.
The clinical course of these infants is complicated by severe respiratory failure and persistent pulmonary hypertension. Despite aggressive management, the mortality and morbidity in these infants remain high (16) .
The outcome of CDH is complicated by the degree of associated pulmonary hypoplasia (12, 14) , and infants often succumb to respiratory failure despite physical repair of the hernia. In both human disease and animal models of CDH the disrupted lung growth is associated with epithelial cell immaturity (1, 10, 11, 17, 21) . Many of these children are diagnosed antenatally, providing the option for prenatal treatment aimed at improving lung growth. Experimental interventions aimed at reducing the developmental arrest and pulmonary hypoplasia include antenatal steroids (9) , tracheal occlusion (6) , and prenatal vitamins A (2, 18, 19) , C (14) and E (3).
A primary area of expertise in this laboratory is the intrauterine transfer of genes into the pulmonary epithelium via the amniotic fluid (15) . We have previously demonstrated that transient in utero over expression of cftr during pulmonary fetal development results in lung epithelial proliferation and accelerated differentiation in the rat, mouse, and nonhuman primate (5, 7, 8) . We reasoned that congenital diaphragmatic hernia might be an ideal candidate for in utero gene therapy because disrupted fetal lung growth plays a significant role in the poor outcome of the disease. Our aim was not to correct the hernia, but rather improve the pulmonary hypoplasia associated with CDH.
We hypothesized that in utero gene therapy with CFTR would achieve this.
This hypothesis was tested in the nitrofen-induced fetal rat model of CDH. CDH is induced by the herbicide Nitrofen following maternal ingestion at day 10 or 13 of gestation (positive vaginal smear = day 1). Dams treated with nitrofen at 10 days gestation have fetuses that develop predominantly left-sided hernias and dams treated with nitrofen at 13 days gestation have fetuses with predominantly right-sided hernias (2) . Litter mates that do not have diaphragmatic hernias also have pulmonary hypoplasia that is intermediate when compared to CDH and controls (4) . We examined the effects of in utero cftr gene transfer on lung growth of nitrofen-treated fetuses treated at either 10 or 13 days gestation.
EXPERIMENTAL PROCEDURES

The Nitrofen CDH Model
Time-dated pregnant Sprague-Dawley rats were housed under standard vivarium conditions. Fetal CDH was induced by orally administering 100 mgs of 2,4-dichlorophenyl-4-nitrophyl ether (Nitrofen; Wako Bioproducts, Richmond, VA) dissolved in 2 ml of olive oil via oral gastric tube following brief isoflurane anesthesia.
Protocol I treated time-dated pregnant Sprague-Dawley rats at 10 days gestation to induce left-sided diaphragmatic hernias followed by in utero gene transfer at 16 days gestation. Protocol II treated time-dated pregnant Sprague-Dawley rats at 13 days gestation to induce right-sided diaphragmatic hernias followed by in utero gene transfer at 16 days gestation (positive vaginal smear=day 1; gestation 22 days). Control animals received 2 ml of olive oil followed by in utero gene transfer at 16 days gestation. The experimental protocols are summarized in Figure 1 .
In Utero Gene Transfer
The fetuses were treated with gene therapy at 16 days gestation with either Ad.CMVEGFP or Av1CF2. This time point has been previously determined by our laboratory to result in the highest lung gene transfer in the rat following intra-amniotic injection (15) . Gene transfer prior to day 16 in the rat results in low (15 days gestation) or no gene transfer (< 14 days gestation). Gene transfer at >18 days gestation results in an immune response to the adenovirus vector and not gene transfer. Thus, in the rat effective gene transfer to the lung can only be accomplished technically efficiently between days 16-18 gestation. AdCMVegfp expresses the reporter green fluorescent protein and was used as a control for injections and a confirmation of transfection efficiency. Av1CF2 is the replication-defective adenovirus that expresses human CFTR. Following induction with 5% Isoflurane in a chamber and under continued inhaled sedation with 2%
Isoflurane with a nose cone the abdomen was cleansed and a laparotomy performed. A midline vertical incision was made in the abdominal wall followed by a second vertical incision into the peritoneal cavity exposing the uterine horns. Each horn was individually exposed and the individual amniotic sacs of the fetuses were visualized. The sacs are injected with a fine gauge needle (27) and resealed almost immediately. A concentration of 10 9 pfu/ml of vector in DMEM was injected into the individual fetal sacs at a volume of 10% of the amniotic fluid volume. This resulted in a final amniotic fluid concentration of 10 8 pfu/ml. This ensured that all of the experimental animals were controlled for surgical manipulation, vector injection and the 10% increase in amniotic fluid volume that occurs with gene transfer. In addition, one group received olive oil followed by intrauterine control virus (EGFP) and another group received olive oil followed by virus containing cftr. These two groups served as additional controls. All animal procedures were reviewed and approved by the IUCAC.
Evaluation of Survival and Hernia Incidence
The fetuses were delivered by caesarian section at 22 days gestation following maternal anesthesia to prevent fetal breathing. The presence of a diaphragmatic hernia was determined by probing for a diaphragmatic defect from the abdomen to the thorax (19) . Fetuses were randomly assigned for biochemical or morphometric analysis.
Survival was evaluated by visual inspection of the fetus for evidence of resorbtion including small size, bone and tissue hypertrophy, and fetal degeneration.
Morphometric Analysis
Following determination of hernia status, the trachea was cannulated with a 24-gauge catheter. The thoracic cavity was widely opened and the lungs were inflated in situ 
Volume proportion of tissues
Volume densities of saccular airspace and parenchyma, airway airspace and airway wall, and vessels were estimated by point-counting morphometry. Following image capture, sections were counted using a lattice of 110 test points. Parenchyma was defined as the gas exchanging compartment that contained the airspaces (saccule ducts and saccules). Airways consisted of conducting airways to the level of the terminal bronchioles.
Measurement of lung complexity
The complexity of the lung was determined by saccular (future airspace) counts 
Real-time PCR for CFTR mRNA
Tissues were placed in RNA Later (Qiagen) at 4°C prior to extraction of total RNA using the Qiagen Total RNA extraction kit. Total RNA was quantitated from the OD 260 and cDNA synthesis was performed. Primers were generated for the target gene (CFTR) by SuperArray Bioscience; these primers, as well as those for the reference gene,
were designed for maximum PCR efficiency. The comparative threshold cycle (C t ) method, also known as the C t method, where
Sample Difference = 2 -Ct was used. CT sample was the Ct value for any sample normalized to the endogenous housekeeping gene and Ct control was the Ct value for the calibrator also normalized to the endogenous housekeeping gene.
Statistical Analysis
Left and right lungs were analyzed separately. No significant differences were detected between the left and the right lung within any treatment group as determined by the paired t-test; therefore data from both lungs were pooled within each treatment. Chisquare analysis was performed on the incidence of survival and hernia. One way analysis of variance (ANOVA) was used for statistical analysis followed by Dunnett's post-test for comparison of control-EGFP animals to all treatment groups. Separate comparisons were made between the nitrofen-treated groups that developed hernias and the nitrofentreated groups that did not develop hernias by unpaired t-tests. A p value of <.05 was considered significant. All values are presented as mean + standard error.
RESULTS
A total of 93 fetuses were injected with control virus following nitrofen treatment and 109 fetuses were injected with virus encoding cftr following nitrofen treatment at 10 days gestation. Following nitrofen treatment at 13 days gestation, a total of 61 fetuses were injected with control virus and 52 fetuses were injected with virus encoding cftr virus. In addition, 58 fetuses received control virus and 61 received virus encoding cftr following ingestion of olive oil without nitrofen.
Intrauterine injections by direct visualization at 16 days gestation afforded the opportunity to evaluate late gestation fetal demise with nitrofen treatment. A significant portion of the fetuses that received nitrofen followed by gene transfer at 16 days gestation were resorbed or dead at the time of caesarian section at 22 days gestation. As shown in Table 1 , nitrofen treatment at 13 days gestation resulted in an overall lower mortality than at 10 days gestation. The difference in mortality rate between the two groups reflected the effects of nitrofen teratogenicity and the gestations at which the fetuses were exposed.
The control animals injected with the EGFP control virus and that did not receive nitrofen had an 88% survival rate.
TEN-DAY NITROFEN TREATMENT GROUP Morphometrics
As previously reported (2), fetuses treated at 10 days gestation developed almost exclusively left-sided hernias. The fetuses treated with nitrofen-EGFP had a 61%
incidence of hernias and the fetuses treated with nitrofen-CFTR had a 52% incidence of hernias. This trend did not reach statistical significance.
The body weights at 22 days gestation in all of the groups exposed to nitrofen at 10 days gestation were significantly lower than the control-EGFP group (p<.001). 
Lung Complexity
Lung Volumes
The data reflective of the lung complexity in the 10 day-nitrofen treatment group is summarized in Figure 2 . The specific fixed lung volumes of all nitrofen 10 daytreatment groups were significantly smaller than the control-EGFP lung volumes and shown in Figure 2a . Treatment with CFTR did not significantly improve the lung volumes in this experimental group. The two parameters that reflected the complexity of the air-exchanging portion of the lung were gas-exchanging surface area and number of saccules per lung. These data are detailed below and shown in Figures 2b and 2c.
Internal gas-exchanging surface area
The inter-airspace wall difference (Lm) did not differ between the nitrofen treated CDH or non-CDH groups. The internal surface area of the gas-exchanging portion of the lung, which is a function of the Lm and the lung volume, was significantly smaller in all of the nitrofen treated groups as compared to the controls. This is demonstrated in Figure 2b .
Total saccules
The total specific saccular number of the groups is shown in Figure 2c . The saccular number was decreased in all of the nitrofen treated animals, though when compared to the control only the nitrofen-EGFP-CDH animals varied significantly from the controls.
THIRTEEN-DAY NITROFEN TREATMENT GROUP Morphometrics
Nitrofen treatment at 13 days gestation resulted in an overall lower mortality than treatment at 10 days gestation ( Table 1 ). The survival rate of the fetuses treated with nitrofen followed by EGFP did not statistically differ from the survival rate of the fetuses treated with nitrofen followed by CFTR. There was a trend towards statistical improvement in the incidence of hernia between the groups but this did not reach statistical significance (68.7% in the nitrofen-EGFP treated group and 55.5% in the nitrofen-CFTR treated group; p=0.1).
The body weights, while generally increased over those treated with nitrofen at 10 days, were still smaller following nitrofen treatment at 13 days compared to the control- 
Lung Complexity
Lung Volumes
In contrast to the fetuses treated with nitrofen at 10 days, there was marked improvement in the fetal lungs that received the CFTR gene following nitrofen treatment at 13 days. These data are summarized in Figure 3 . There was an increase in the specific lung volumes in the CFTR treatment groups with the difference reaching statistical significance between the nitrofen non-CDH groups (Figure 3a) . The parameters reflective of air-exchanging portion of the lung significantly improved in the nitrofen-CFTR treated animals as compared to the nitrofen-EGFP animals. These were the gas-exchanging surface area and number of saccules per lung. These data are detailed below and summarized in Figures 3b and 3c .
Internal surface area
The inter-airspace wall difference (Lm) was decreased in the nitrofen-CFTR treated lungs and comparable to controls. The decreased Lm reflected a more complex air-exchanging unit. The internal surface area of the gas-exchanging portion of the lung, which is a function of the Lm and the lung volume, was significantly improved in the nitrofen-CFTR treated lungs. Both the CDH and non-CDH CFTR treated groups varied significantly from their respective EGFP treated groups (Figure 3b ).
Total saccules
In addition to their increased lung volumes the nitrofen-CFTR treated fetuses had increased numbers of saccules per unit area of lung. Both groups of nitrofen-CFTR treated animals had significantly higher numbers of saccules/cm2 as compared to their respective nitrofen-EGFP groups. This was in both the CDH and non-CDH groups.
Larger lungs with more saccules/area resulted in significantly increased numbers of saccules in the lungs of both of the nitrofen-CFTR treated groups. As shown in Figure   3c ., the specific number of saccules in the nitrofen-CFTR groups approached normal.
Lung Histology
The histologic appearance between the 13 day treated nitrofen-EGFP and nitrofen-CFTR groups was markedly different. This histology reflected the increased air exchanging area in the CFTR treated lungs. The animals treated with nitrofen-EGFP animals with CDH (Figure 4a ) had the markedly thick interstitium and compressed airspaces seen previously with CDH and indicative of developmental arrest (4). This is caused by the presence of fewer saccules, thicker septa and decreased width of the airspace lumens. The animals in the nitrofen-EGFP group without hernias had slightly improved histology (Figure 4c ), but continued to have fewer terminal bronchi and saccular dilatation that the controls. In contrast, the nitrofen animals treated with CFTR had thinner interstitium indicative of a more developed lung. Even if the nitrofen-CFTR animal had a CDH (Figure 4b) , there was improvement in histology with thinning of the interstitium and more saccular airspace present. The histologic appearance of nitrofen-CFTR animals ( Figure 4d ) more closely matched the appearance of the control animals that had not been exposed to nitrofen (Figure 4e ).
Volume Proportion of Tissues
As can be expected by histology in Figure 4 , the volume proportion of saccular air was increased with CFTR treatment and the volume proportion of parenchyma decreased with CFTR treatment. The thinning of the septa was indicative of more mature complex lung. This is demonstrated in Figure 5 .
CFTR GENE TRANSFER
In utero CFTR gene therapy at 16 days gestation resulted in marked improvement of lung development in the fetuses treated with nitrofen at 13 days gestation but negligible improvement following nitrofen treatment at 10 days gestation. CFTR mRNA was quantitated in the lungs of the fetuses to determine if the treatment outcomes differed because of gene transfer efficiency. CFTR mRNA was measured in the lungs at 22 days gestation using real time PCR in each of the groups. Following nitrofen exposure at 10 days gestation, the relative expression of lung CFTR mRNA was not increased in the fetal group that received the CFTR gene compared to the group that received the EGFP control virus (0.2+0.1, n=8). However, after exposure to nitrofen at 13 days gestation, the relative expression of CFTR mRNA was increased (5.7+1.8, n=8) in the lungs of fetuses that received the CFTR virus over those that received the EGFP virus (p<0.05).
Therefore, in utero gene transfer efficiency to the lung was affected by the gestational age at which nitrofen exposure occurred. As disruption of lung development also correlates with the gestation at which nitrofen exposure occurs, these results confirmed previous findings that in utero gene transfer efficiency is affected by the developmental maturity of the lung (19) .
DISCUSSION
Severe pulmonary hypoplasia remains a major cause of the high morbidity and mortality in CDH yet it's precise etiology remains elusive (14) . In this study, the CDH lung was shown to be developmentally immature and that CFTR over expression overcomes this defect. All these studies are consistent with CFTR acting as an accelerator of lung development.
The primary limitation of the nitrofen induced rat hernia model is the involvement of multiple organ defects. Thus, it is impossible to evaluate the long term effects of in utero CFTR gene therapy on lung function. In addition, the gene therapy window in rats is much shorter than humans. As shown by the gene transfer failure in 10 day nitrofen studies, hernia development can affect in utero delivery of the gene. The lung volumes, saccules per area, and internal surface area in the nitrofen-CFTR treated groups did not significantly differ from their nitrofen-EGFP treated counterparts following treatment at 10 days gestation ( p<.05 difference between control-EGFP group and groups annotated with * ). Morphometry was performed using identification numbers with the treatment groups unidentified. Analysis was performed by two blinded investigators. Marked improvement in the fetal lungs that received the CFTR gene following nitrofen treatment at 13 days is demonstrted. There was an increase in the specific lung volumes in the CFTR treated groups with the difference reaching statistical significance in the non-CDH group (Figure 3a) , and the gas-exchanging surface area and number of saccules per lung improved in the CFTR treated groups (p<0.05 difference between control-EGFP group and groups annotated with a; b-p<0.05 between nitrofen-CDH groups, c -p<0.05 between nitrofen-non-CDH groups). 
